Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674074 | 0.84 | CA9 (0.50) | CYP1A1CYP1B1AOC3MAPTTDP1 | |
| SCHEMBL30701949 | 0.84 | CA9 (0.50) | CYP1A1CYP1B1AOC3MAPTTDP1 | |
| SCHEMBL11230766 | 0.83 | MAPT (0.38) | CYP1A1CYP1B1AOC3MAPTTDP1 | |
| SCHEMBL2118323 | 0.81 | KDM4E (0.42) | MAPTTDP1ALDH1A1CYP19A1ACHE | |
| SCHEMBL7534903 | 0.81 | MEN1 (0.41) | MAPTALDH1A1CYP19A1ACHEPOLB | |
| SCHEMBL7528395 | 0.79 | AMY1A (0.39) | MAPTTDP1ALDH1A1POLBKDM4E | |
| SCHEMBL28084463 | 0.79 | CA2 (0.40) | MAPTTDP1ALDH1A1KDM4EHPGD | |
| SCHEMBL42242 | 0.78 | SMN1; SMN2 (0.50) | CYP1A1CYP1B1MAPTALDH1A1CYP19A1 | |
| SCHEMBL5248756 | 0.77 | MAPT (0.41) | CYP1A1CYP1B1AOC3MAPTTDP1 | |
| SCHEMBL4635687 | 0.77 | AOC3 (0.41) | CYP1A1CYP1B1AOC3MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389214-A2 | USE OF TRIMETHOXYBENZYL ACETYLSINAPATE, ADVANTAGEOUSLY IN COMBINATION WITH AT LEAST ONE SUNSCREEN, FOR PROTECTING THE SKIN | Thorel, Jean-Noël (FR) | 2024-06-26 | — | — | EP | claimed |
| EP-4368621-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | Applied Pharmaceutical Science, Inc. (CN) | 2024-05-15 | — | — | EP | claimed |
| EP-3466419-B1 | USE OF TRIMETHOXYBENZYL ACETYLSINAPATE, ADVANTAGEOUSLY IN COMBINATION WITH AT LEAST ONE SUNSCREEN, FOR PROTECTING THE SKIN | THOREL JEAN NOEL (FR) | 2024-05-08 | — | — | EP | claimed |
| CN-117561259-A | Preparation method of nitrogen-containing polycyclic condensed ring compound, intermediate and application thereof | 北京志健金瑞生物医药科技有限公司 | 2024-02-13 | — | — | CN | claimed |
| EP-4297774-A1 | VACCINE FOR THERAPEUTIC OR PROPHYLACTIC TREATMENT OF MYASTHENIA GRAVIS | Curavac Europe (BE) | 2024-01-03 | — | — | EP | claimed |
| EP-4272000-A2 | LINKER STRUCTURES WITH MINIMAL SCAR FOR ENZYMATIC SYNTHESIS | Microsoft Technology Licensing LLC (US) | 2023-11-08 | — | — | EP | claimed |
| US-20230151047-A1 | LINKER STRUCTURES WITH MINIMAL SCAR FOR ENZYMATIC SYNTHESIS | MICROSOFT TECHNOLOGY LICENSING, LLC | 2023-05-18 | — | — | US | claimed |
| US-11591361-B2 | Linker structures with minimal scar for enzymatic synthesis | MICROSOFT TECHNOLOGY LICENSING, LLC (US) | 2023-02-28 | — | — | US | claimed |
| CN-115594678-A | Preparation method of nitrogen-containing polycyclic fused ring compound, intermediate and application thereof | 北京志健金瑞生物医药科技有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| WO-2023280073-A1 | METHOD FOR PREPARING NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUND, AND INTERMEDIATE AND USE OF COMPOUND | 北京志健金瑞生物医药科技有限公司 | 2023-01-12 | — | — | WO | claimed |
| US-4544652-A | α-Hydroxyethylphosphinates, and their use as fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-10-01 | — | — | US | claimed |
| EP-0054309-B1 | LONG DURATION NEUROMUSCULAR BLOCKING AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-08-22 | — | — | EP | claimed |
| EP-0093010-A2 | Alpha-hydroxyethylphosphinates, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-11-02 | — | — | EP | claimed |
| EP-0080682-A1 | Bisisoquinolinium compound, pharmaceutical compositions and synthesis | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-06-08 | — | — | EP | claimed |
| EP-0054309-A1 | Long duration neuromuscular blocking agents, pharmaceutical compositions containing them and processes for their preparation | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-06-23 | — | — | EP | claimed |
| US-4333936-A | Novel amidino-benzylpyrimidines, processes for their manufacture and antibacterial and antiprotozoal use thereof | BASF AKTIENGESELLSCHAFT (DE) | 1982-06-08 | — | — | US | claimed |
| EP-0000336-B1 | N-BENZYLPYRIMIDINYL-AMIDINES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1981-04-15 | — | — | EP | claimed |
| US-4092474-A | Cephalosporins having a metaloxy group in 3-substituent | SHIONOGI & CO., LTD. (JA) | 1978-05-30 | — | — | US | claimed |
| US-4075340-A | ANTIINFLAMMATORY, ANTIARRYTHMIC, ANTICOAGULANTS | PARCOR (FR) | 1978-02-21 | — | — | US | claimed |
| US-3932423-A | TREATMENT OF PSYCHOLOGICAL DISORDERS | YOSHITOMI PHARMACEUTICAL INDUSTRIES (JA) | 1976-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151047-A1 | LINKER STRUCTURES WITH MINIMAL SCAR FOR ENZYMATIC SYNTHESIS | RNGTT, MMP1, UNG | CYP1A1 2172/4885CYP1B1 1365/4885AOC3 719/4885 |
| US-11591361-B2 | Linker structures with minimal scar for enzymatic synthesis | RNGTT, MMP1, UNG | CYP1A1 2172/4885CYP1B1 1365/4885AOC3 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.